Page 63 - Williams Hematology ( PDFDrive )

38 Part I: Clinical Evaluation of the Patient Chapter 3: Examination of the Marrow 39

59. Hot A, Jaisson I, Girard C, et al: Yield of bone marrow examination in diagnosing the 81. Della Porta MG, Picone C, Pascutto C, et al: Multicenter validation of a reproduc-
source of fever of unknown origin. Arch Intern Med 169:2018–2023, 2009. ible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes:
60. Ben-Baruch S, Canaani J, Braunstein R, et al: Predictive parameters for a diagnostic results of a European LeukemiaNET study. Haematologica 97:1209–1217, 2012.
bone marrow biopsy specimen in the work-up of fever of unknown origin. Mayo Clin 82. Porwit A, van de Loosdrecht AA, Bettelheim P, et al: Revisiting guidelines for inte-
Proc 87:136–142, 2012. gration of flow cytometry results in the WHO classification of Myelodysplastic Syn-
61. Eid A, Carion W, Nystrom JS: Differential diagnoses of bone marrow granuloma. West dromes-proposal from the International/European LeukemiaNet Working Group for
J Med 164:510–515, 1996. Flow Cytometry in MDS (IMDSFlow). Leukemia 28:1793–1798, 2014.
62. Norgard MJ, Carpenter JTJ, Conrad ME: Bone marrow necrosis and degeneration. Arch 83. Alhan C, Westers TM, Cremers EM, et al: High flow cytometric scores identify adverse
Intern Med 139:905, 1979. prognostic subgroups within the revised international prognostic scoring system for
63. Seaman JP, Kjeldsberg CR, Linker A: Gelatinous transformation of the bone marrow. myelodysplastic syndromes. Br J Haematol 167:100–109, 2014.
Hum Pathol 9:685, 1978. 84. Tembhare P, Yuan CM, Xi L, et al: Flow cytometric immunophenotypic assessment
64. Rosse C, Krauner MJ, Dillon TL, et al: Bone marrow cell populations of normal infants: of T-cell clonality by Vbeta repertoire analysis: detection of T-cell clonality at diag-
The predominance of lymphocytes. J Lab Clin Med 89:1225, 1977. nosis and monitoring of minimal residual disease following therapy. Am J Clin Pathol
65. Dresch C, Faille A, Poirier O, Kadouche J: The cellular composituon of the granylocyte 135:890–900, 2011.
series in the normal human bone marrow according to the volume of the sample. J Clin 85. Schrappe M: Minimal residual disease: Optimal methods, timing, and clinical rel-
Pathol 27:106, 1974. evance for an individual patient. Hematology Am Soc Hematol Educ Program 2012:
66. Mufti GJ, Bennett JM, Goasguen J, et al: Diagnosis and classification of myelodysplastic 137–142, 2012.
syndrome: International Working Group on Morphology of myelodysplastic syndrome 86. Campana D: Should minimal residual disease monitoring in acute lymphoblastic leu-
(IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts kemia be standard of care? Curr Hematol Malig Rep 7:170–177, 2012.
and ring sideroblasts. Haematologica 93:1712–1717, 2008. 87. Paietta E: Minimal residual disease in acute myeloid leukemia: Coming of age. Hema-
67. Goasguen JE, Bennett JM, Bain BJ, et al: Morphological evaluation of monocytes and tology Am Soc Hematol Educ Program 2012:35–42, 2012.
their precursors. Haematologica 94:994–997, 2009. 88. Ghia P: A look into the future: Can minimal residual disease guide therapy and predict
68. Janka GE, Lehmberg K: Hemophagocytic syndromes—an update. Blood Rev 28: prognosis in chronic lymphocytic leukemia? Hematology Am Soc Hematol Educ Pro-
135–142, 2014. gram 2012:97–104, 2012.
69. DePalma L: The effect of decalcification and choice of fixative on histiocytic iron in 89. Strati P, Keating MJ, O’Brien SM, et al: Eradication of bone marrow minimal residual
bone marrow core biopsies. Biotech Histochem 71:57–60, 1996. disease may prompt early treatment discontinuation in CLL. Blood 123:3727–3732,
70. Bain BJ: The bone marrow aspirate of healthy subjects. Br J Haematol 94:206–209, 1996. 2014.
71. Longacre TA, Foucar K, Crago S, et al: Hematogones: A multiparameter analysis of 90. Hart AJ, Jagasia MH, Kim AS, et al: Minimal residual disease in myeloma: Are we there
bone marrow precursor cells. Blood 73:543–552, 1989. yet? Biol Blood Marrow Transplant 18:1790–1799, 2012.
72. Jaffe ES, Harris NL, Stein H: WHO Classification of Tumours of Haematopoietic and 91. Preti RA, Chan WS, Kurtzberg J, et al: Multi-site evaluation of the BD Stem Cell Enu-
Lymphoid Tissue (IARC WHO Classification of Tumours), 4th ed. The International meration Kit for CD34 cell enumeration on the BD FACSCanto II and BD FACSCalibur
Agency for Research on Cancer, Lyon, France, 2008. flow cytometers. Cytotherapy 16:1558–1574,2014.
73. Stelzer GT, Marti G, Hurley A, et al: U.S.–Canadian Consensus recommendations on 92. Beksac M, Preffer F: Is it time to revisit our current hematopoietic progenitor cell quan-
the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Standard- tification methods in the clinic? Bone Marrow Transplant 47:1391–1396, 2012.
ization and validation of laboratory procedures. Cytometry 30:214–230, 1997. 93. Preis M, Lowrey CH: Laboratory tests for paroxysmal nocturnal hemoglobinuria. Am J
74. Zare H, Bashashati A, Kridel R, et al: Automated analysis of multidimensional flow Hematol 89:339–341, 2014.
cytometry data improves diagnostic accuracy between mantle cell lymphoma and small 94. Borowitz MJ, Craig FE, Digiuseppe JA, et al: Guidelines for the diagnosis and monitor-
lymphocytic lymphoma. Am J Clin Pathol 137:75–85, 2012. ing of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry.
75. Sewell WA, Smith SA: Polychromatic flow cytometry in the clinical laboratory. Pathol- Cytometry B Clin Cytom 78:211–230, 2010.
ogy 43:580–591, 2011. 95. Jamshidi K, Swaim WR: Bone marrow biopsy with unaltered architecture: A new
76. Aghaeepour N, Finak G, Hoos H, et al: Critical assessment of automated flow cytome- biopsy device. J Lab Clin Med 77:335, 1971.
try data analysis techniques. Nat Methods 10:228–238, 2013. 96. Ellis LD, Jensen WN, Westerman MP: Needle biopsy of bone marrow: An experience
77. Harrington AM, Olteanu H, Kroft SH: A dissection of the CD45/side scatter “blast with 1,445 biopsies. Arch Intern Med 114:213, 1964.
gate.” Am J Clin Pathol 137:800–804, 2012. 97. Glaser K, Limarzi LR, Poncher HG: Cellular composition of the bone marrow in nor-
78. Fromm JR, Wood BL: A six-color flow cytometry assay for immunophenotyping classi- mal infants and children. Pediatrics 6:789, 1950.
cal Hodgkin lymphoma in lymph nodes. Am J Clin Pathol 141:388–396, 2014. 98. Bain BJ: Ethnic and sex differences in the total and differential white cell count and
79. Tang G, Jorgensen LJ, Zhou Y, et al: Multi-color CD34(+) progenitor-focused flow platelet count. J Clin Pathol 49:664–666, 1996.
cytometric assay in evaluation of myelodysplastic syndromes in patients with post can-
cer therapy cytopenia. Leuk Res 36:974–981, 2012.
80. Truong F, Smith BR, Stachurski D, et al: The utility of flow cytometric immunopheno-
typing in cytopenic patients with a non-diagnostic bone marrow: A prospective study.
Leuk Res 33:1039–1046, 2009.

Kaushansky_chapter 03_p0027-0040.indd 39 17/09/15 5:38 pm